Compare ADMA Biologics Inc (ADMA) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Roblox Corp — how do they compare? ADMA Biologics Inc trades at $9.83 (market cap $2.22B), while Roblox Corp trades at $35.5 (market cap $25.87B). The key difference: Roblox Corp is far larger — about 11.7× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| ADMA | RBLX | |
|---|---|---|
Market Cap | $2.22B | $25.87B |
Sector | Health | Media |
52-Week High | $20.38 | $141.56 |
52-Week Low | $7.60 | $35.60 |
Enterprise Value | $2.29B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
Roblox (RBLX) trades at $35.33, down 4.64% on the day, amid a bearish technical signal and negative investor sentiment driven by multiple class-action lawsuits. The company shows strong revenue growth, with 2025 revenue reaching $4.89 billion, but remains unprofitable with a net income margin of -17.61%. Recent earnings have beaten expectations, yet management withdrew full-year 2026 guidance, increasing uncertainty.
The outlook is mixed: robust user engagement and revenue growth offer long-term potential, but near-term risks from legal challenges and persistent losses warrant caution. Analyst consensus is a Buy with a $45.67 price target, suggesting upside if execution improves, though volatility from negative news flow may pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
